Evidence map›Paper›PMID 31741616›Full record

ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2019

Primary Plasma Cell Leukemia: A Retrospective Study of a Rare Disease From Tertiary Cancer Centre From India.

Neha Yadav, Mukul Aggarwal, Pallavi Mehta, Jyotsna Kapoor, Shinto Francis Thekkudan, Pragya Bhandari, Priyanka Soni, Rayaz Ahmed, Dinesh Bhurani, Narendra Agrawal

Abstract read
In one paragraph

Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Improved Outcome of Primary Plasma Cell Leukemia in the Current Era with the Use of Novel Agents and Autologous Bone Marrow Transplants-A Single Centre Experience.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Neha YadavDepartment of Hemato-Oncology, Rajiv Gandhi Cancer Institute, Rajiv Gandhi Cancer Institute & Research Centre, Sector-5, Rohini, 110085 New Delhi, India.
Mukul AggarwalDepartment of Hemato-Oncology, Rajiv Gandhi Cancer Institute, Rajiv Gandhi Cancer Institute & Research Centre, Sector-5, Rohini, 110085 New Delhi, India.
Pallavi MehtaDepartment of Hemato-Oncology, Rajiv Gandhi Cancer Institute, Rajiv Gandhi Cancer Institute & Research Centre, Sector-5, Rohini, 110085 New Delhi, India.
Jyotsna KapoorDepartment of Hemato-Oncology, Rajiv Gandhi Cancer Institute, Rajiv Gandhi Cancer Institute & Research Centre, Sector-5, Rohini, 110085 New Delhi, India.
Shinto Francis ThekkudanDepartment of Hemato-Oncology, Rajiv Gandhi Cancer Institute, Rajiv Gandhi Cancer Institute & Research Centre, Sector-5, Rohini, 110085 New Delhi, India.
Pragya BhandariDepartment of Hemato-Oncology, Rajiv Gandhi Cancer Institute, Rajiv Gandhi Cancer Institute & Research Centre, Sector-5, Rohini, 110085 New Delhi, India.
Priyanka SoniDepartment of Hemato-Oncology, Rajiv Gandhi Cancer Institute, Rajiv Gandhi Cancer Institute & Research Centre, Sector-5, Rohini, 110085 New Delhi, India.
Rayaz AhmedDepartment of Hemato-Oncology, Rajiv Gandhi Cancer Institute, Rajiv Gandhi Cancer Institute & Research Centre, Sector-5, Rohini, 110085 New Delhi, India.
Dinesh BhuraniDepartment of Hemato-Oncology, Rajiv Gandhi Cancer Institute, Rajiv Gandhi Cancer Institute & Research Centre, Sector-5, Rohini, 110085 New Delhi, India.
Narendra AgrawalDepartment of Hemato-Oncology, Rajiv Gandhi Cancer Institute, Rajiv Gandhi Cancer Institute & Research Centre, Sector-5, Rohini, 110085 New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasma cell leukemia (PCL) is an aggressive rare leukemic variant of multiple myeloma (MM). We aim to present 4 years data on clinical profile and treatment outcomes of Primary PCL (PPCL) patients treated at tertiary care cancer centre from Northern India. To analyse response and safety profile of a PPCL with or without stem cell transplantation. Retrospectively reviewed and analysed PPCL patient's data at our centre from January-2013 to June-2017. Total 11 PPCL patients diagnosed among 240 MM patients during study period. Eight were males. Only 10 patients were started on treatment. Four (n = 4/10) patients underwent stem cell transplantation. Overall response rate was 70% (n = 7). Eleven culture positive bacterial infections (bloodstream = 2, urinary tract = 3; pulmonary = 6) were recorded. Four patients had fungal infections. One patient had Herpes Zoster infection. Relapse rate of entire cohort was 50% (n = 5). Median PFS and OS of entire cohort was 11 months (95% confidence interval 6.3-15.6) and 21 months (95% C.I. 1-49.8) respectively. The estimated PFS and OS at 1 year of transplanted versus nontransplanted patients were 71% + 24% versus 0% (

Indexed as

Multiple myelomaOverall survivalPrimary plasma cell leukemiaStem cell transplantation

Identifiers

PMID31741616
PMCPMC6825115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.